[Molecular Pathogenesis of Muscular Diseases]

Overview

Journal Naturwissenschaften

Specialty Science

Date 1996 Dec 1

PMID 9036337

Authors

K Ohlendieck

Affiliations

Soon will be listed here.

Abstract

Recent advances in the field of molecular myology have provided significant insight into the pathological mechanisms underlying a variety of neuromuscular disorders. Genetic abnormalities can now be linked to primary and secondary pathophysiological changes in muscle fibres which compromise structural, metabolic, regulatory or contractile mechanisms. Ion channel myopathies such as paramyotonia congenita, hyper- and hypokalaemic periodic paralysis, myotonia congenita, episodic ataxia and malignant hyperthermia were established as linked to mutations in genes encoding the sodium channel, dihydropyridine receptor, chloride channel, potassium channel and the ryanodine receptor calcium release channel, respectively. Metabolic disorders affecting skeletal muscle were found to be due to deficiencies in a variety of enzymes. Identification of defects in components belonging to the gigantic dystrophin-glycoprotein complex led to the discovery of the molecular pathogenesis of Duchenne muscular dystrophy and related disorders. Based on these molecular findings, it is now feasible to design and evaluate new techniques such as gene and myoblast transfer therapy in order to replace defective components in diseased muscle fibres.

References

Tinsley J, Blake D, Roche A, Fairbrother U, Riss J, Byth B . Primary structure of dystrophin-related protein. Nature. 1992; 360(6404):591-3. DOI: 10.1038/360591a0. View

Nigro G, Politano L, Nigro V, Petretta V, Comi L . Mutation of dystrophin gene and cardiomyopathy. Neuromuscul Disord. 1994; 4(4):371-9. DOI: 10.1016/0960-8966(94)90073-6. View

Ervasti J, Campbell K . A role for the dystrophin-glycoprotein complex as a transmembrane linker between laminin and actin. J Cell Biol. 1993; 122(4):809-23. PMC: 2119587. DOI: 10.1083/jcb.122.4.809. View

Blake D, Tinsley J, Davies K . The emerging family of dystrophin-related proteins. Trends Cell Biol. 1994; 4(1):19-23. DOI: 10.1016/0962-8924(94)90034-5. View

George Jr A, Crackower M, Abdalla J, Hudson A, Ebers G . Molecular basis of Thomsen's disease (autosomal dominant myotonia congenita). Nat Genet. 1993; 3(4):305-10. DOI: 10.1038/ng0493-305. View

Krivosic-Horber R . Malignant hyperthermia. Treatment of the acute episode. Acta Anaesthesiol Belg. 1990; 41(2):83-6. View

Karpati G, Acsadi G . The potential for gene therapy in Duchenne muscular dystrophy and other genetic muscle diseases. Muscle Nerve. 1993; 16(11):1141-53. DOI: 10.1002/mus.880161102. View

Lehmann-Horn F, Rudel R . Molecular pathophysiology of voltage-gated ion channels. Rev Physiol Biochem Pharmacol. 1996; 128:195-268. DOI: 10.1007/3-540-61343-9_9. View

Yoshida M, Ozawa E . Glycoprotein complex anchoring dystrophin to sarcolemma. J Biochem. 1990; 108(5):748-52. DOI: 10.1093/oxfordjournals.jbchem.a123276. View

10.

Smit L, Hageman G, Veldman H, Molenaar P, Oen B, Jennekens F . A myasthenic syndrome with congenital paucity of secondary synaptic clefts: CPSC syndrome. Muscle Nerve. 1988; 11(4):337-48. DOI: 10.1002/mus.880110410. View

11.

Roa B, Garcia C, Pentao L, Killian J, Trask B, Suter U . Evidence for a recessive PMP22 point mutation in Charcot-Marie-Tooth disease type 1A. Nat Genet. 1993; 5(2):189-94. DOI: 10.1038/ng1093-189. View

12.

Monaco A, Neve R, Bertelson C, Kurnit D, Kunkel L . Isolation of candidate cDNAs for portions of the Duchenne muscular dystrophy gene. Nature. 1986; 323(6089):646-50. DOI: 10.1038/323646a0. View

13.

Ohno K, Wang H, Milone M, Bren N, Brengman J, Nakano S . Congenital myasthenic syndrome caused by decreased agonist binding affinity due to a mutation in the acetylcholine receptor epsilon subunit. Neuron. 1996; 17(1):157-70. DOI: 10.1016/s0896-6273(00)80289-5. View

14.

Siciliano G, Fanin M, Angelini C, Pollina L, Miorin M, Saad F . Prevalent cardiac involvement in dystrophin Becker type mutation. Neuromuscul Disord. 1994; 4(4):381-6. DOI: 10.1016/0960-8966(94)90074-4. View

15.

Maekawa M, Sudo K, Kanno T, Li S . Molecular characterization of genetic mutation in human lactate dehydrogenase-A (M) deficiency. Biochem Biophys Res Commun. 1990; 168(2):677-82. DOI: 10.1016/0006-291x(90)92374-9. View

16.

Monaco A, Bertelson C, Moser H, Kunkel L . An explanation for the phenotypic differences between patients bearing partial deletions of the DMD locus. Genomics. 1988; 2(1):90-5. DOI: 10.1016/0888-7543(88)90113-9. View

17.

Lim L, Duclos F, Broux O, Bourg N, Sunada Y, Allamand V . Beta-sarcoglycan: characterization and role in limb-girdle muscular dystrophy linked to 4q12. Nat Genet. 1995; 11(3):257-65. DOI: 10.1038/ng1195-257. View

18.

Ohlendieck K, Matsumura K, Ionasescu V, Towbin J, Bosch E, Weinstein S . Duchenne muscular dystrophy: deficiency of dystrophin-associated proteins in the sarcolemma. Neurology. 1993; 43(4):795-800. DOI: 10.1212/wnl.43.4.795. View

19.

Kress W, Muller E, Kausch K, Kullmann F, Mostacciuolo M, Rietschel M . Multipoint linkage mapping of the Emery-Dreifuss muscular dystrophy gene. Neuromuscul Disord. 1992; 2(2):111-5. DOI: 10.1016/0960-8966(92)90042-5. View

20.

Tsujino S, Shanske S, Sakoda S, FENICHEL G, DiMauro S . The molecular genetic basis of muscle phosphoglycerate mutase (PGAM) deficiency. Am J Hum Genet. 1993; 52(3):472-7. PMC: 1682163. View